Press Coverage

  • KC Register News Site

    On Friday Metabolix, Inc. (NASDAQ:MBLX) share price closed at $0.59. Company return on equity (ROE) is -159.70%. Metabolix, Inc. (NASDAQ:MBLX) is -85.06% away from its 52 week high and its 52 week range is $0.54 – $3.98. Metabolix, Inc. (NASDAQ:MBLX) said that, it is exiting that market to focus on crop enhancement technology. The decision has prompted London-based bioscience firm Cellulac plc — an investor in Metabolix — to again propose a merger of the two companies.

  • Plastics & Rubber World

    Bioplastics maker Metabolix is exiting the market to focus on crop enhancement technology. Company officials said in May that Metabolix was considering strategic alternatives, including a possible sale. The announcement came less than two months after Metabolix said it had a plan in place to bring its biopolymers production back to the United States. Cellulac chief executive Gerard Brandon said Metabolix declined a merger offer his firm had made in May without even informing shareholders.

  • Plastics News

    Bioplastics maker Metabolix Inc. is exiting that market to focus on crop enhancement technology. The decision has prompted London-based bioscience firm Cellulac plc — an investor in Metabolix — to again propose a merger of the two companies.

  • Plastics Today

    CEO of Cellulac said "A merger with Cellulac, based on the biopolymer intellectual property and associated institutional knowledge, would reduce Metabolix development overhead to a more manageable level where manufacturing license fees and future royalties would transform Metabolix, for the first time in 24 years, into a profitable part of an enlarged bio-based company"

  • NNFCC

    Speculation that Cellulac are in talks to acquire Metabolix’s technology. This would make sense if Cellulac were to combine Metabolix and their own technology, which could reduce the cost of producing PHA biopolymers.